Pharma Super Bowl Commercials: Is This For Real?

Pharma doesn’t buy Super Bowl ads to explain molecules. It buys them to signal inevitability.

Tomorrow night, as Super Bowl 60 kicks off, a select group of drugmakers and healthcare companies will spend millions to reach the broadest possible audience. Some campaigns are about normalizing behavior and quietly expanding the top of the funnel for therapies that are already built, approved, and ready to scale. Others are more confrontational, focused on who gets to control access, define legitimacy, and capture value in the most important drug category of the decade.

In this edition of Is This For Real?, I’ll look at two Super Bowl pharma storylines and what they reveal about how science, regulation, and innovation collide once medicine goes fully mainstream.

Novartis’ Super Bowl campaign is not really about football, celebrities, or advertising flair. It is about getting men to take the first step into the prostate cancer care pathway.

That first step is PSA. Prostate-specific antigen is a protein produced by the prostate that can be measured with a simple blood test. Elevated PSA levels do not diagnose cancer on their own, but they are often the trigger for further evaluation, referral to a urologist, and downstream imaging or biopsy. For decades, PSA testing has been the front door to prostate cancer detection, yet many men avoid screening altogether due to fear, stigma, or misconceptions about invasive exams.

Novartis is deliberately addressing that bottleneck. By reframing prostate screening around a blood test and away from the digital rectal exam, the company is trying to lower psychological barriers at the very top of the funnel. More PSA testing means more diagnoses, earlier workups, and more patients entering structured prostate cancer care.

That matters because PSA screening is how patients eventually reach PSMA-based treatment. Prostate-specific membrane antigen, or PSMA, is a protein found on the surface of many prostate cancer cells, especially in advanced disease. Unlike PSA, PSMA is not a screening biomarker. It is identified using PSMA-PET imaging and serves as both a staging tool and a therapeutic target.

This is where Novartis’ Pluvicto comes in. Pluvicto is a radioligand therapy that binds to PSMA on prostate cancer cells, is internalized, and delivers targeted radiation directly inside the tumor. Rather than broadly poisoning dividing cells like chemotherapy, Pluvicto uses PSMA expression to concentrate radiation where the cancer lives.

Earlier last year, Novartis secured FDA approval to move Pluvicto into an earlier, pre-chemotherapy setting, a label expansion that roughly triples the eligible patient population and anchors the company’s ambition for the drug to reach more than $5 billion in peak annual sales. That expansion only works if patients are identified early enough to undergo PSMA imaging and qualify for PSMA-targeted therapy before exhausting other options.

Seen through that lens, the Super Bowl ad is not a branding exercise. It is a systems-level investment. Novartis is not advertising Pluvicto to consumers. It is strengthening the upstream screening behavior that feeds the entire PSMA ecosystem.

The science is ready. The therapy is approved. The infrastructure is built. The remaining constraint is whether patients show up early enough for the system to work.

That is what this Super Bowl ad is really testing.

If the Novartis ad is about widening the top of the funnel, the Super Bowl spots from Hims & Hers and Novo Nordisk are about something more existential. Control.

At the surface level, both companies are advertising access to GLP-1 weight loss drugs. Underneath, they are fighting over who gets to define legitimacy, exclusivity, and value in the most important drug category of the decade.

Novo Nordisk’s message is straightforward. Its oral GLP-1, Wegovy, represents the culmination of years of clinical development, formulation science, regulatory risk, and manufacturing scale. Oral delivery is not a cosmetic upgrade. Peptide drugs are fragile, easily degraded in the gut, and historically required injection for a reason. Novo’s pill works because of proprietary formulation strategies that protect the drug through digestion and enable systemic absorption. That innovation is precisely what Novo believes should be protected, monetized, and defended.

Hims is making a different argument. By advertising compounded versions of GLP-1 therapies and positioning itself as a challenger to “the system,” it is testing how far brand exclusivity really extends once demand outstrips access. The company is not running clinical trials or seeking FDA approval for a new drug. It is leveraging regulatory gray zones around compounding, personalization, and telehealth distribution to move faster than traditional pharma ever could.

This is not just a legal fight. It is a strategic one.

If telehealth platforms can broadly market compounded versions of newly approved blockbuster drugs, the incentive structure that funds pharmaceutical innovation starts to fray. Years of R&D, failed programs, and capital risk are justified by a limited window of market exclusivity. Once that window becomes porous, the economics change quickly. Fewer companies take big swings. Fewer hard problems get solved.

That does not mean access is unimportant. It means access without innovation is not sustainable.

I was glad to see that the FDA has stepped in decisively, referring Hims & Hers to the Justice Department and moving to restrict how compounded GLP-1 drugs can be marketed and described to consumers. By explicitly rejecting claims of equivalence between compounded versions and FDA-approved drugs like Wegovy, regulators are drawing a clear boundary around compounding and signaling that mass-market substitution is not what the exemption was designed for. In doing so, the FDA is siding with branded pharma on a core principle: innovation requires enforceable periods of protection, and access cannot come at the expense of regulatory rigor or the incentives that make breakthrough drugs possible in the first place.

This is why these Super Bowl ads matter. They are not selling weight loss. They are staking claims on who gets to define the rules of modern biopharma.

And whether innovation remains worth protecting at all.

Here is what I am into:

What I’m mourning
Tesla model S wasn’t just a car, it was the proof that electric vehicles could be fast, beautiful, and genuinely desirable, not a compromise made out of guilt. Tesla killed the model. Even if it now represents only ~5% of Tesla’s sales, killing the Model S feels like walking away from the product that launched the EV movement I actually believe in, in favor of a automated future that’s far less proven.

What shocked me
Crypto isn’t just getting hacked, it’s getting robbed. This article reports a wave of home invasions and kidnappings where criminals target ordinary investors and force them at gunpoint to transfer funds, because crypto transactions are fast and irreversible. The unsettling takeaway is that as crypto goes mainstream, the risk is no longer just digital. It can follow you home.

What is giving me pause
A New York Times investigation digs into the science behind Guardian Caps and finds a gap between how the NFL promotes them and what the evidence actually shows. You’ll see the bulky helmet add-ons on TV this Super Bowl Sunday, framed as a safety advance, even as the manufacturer is careful to say they blunt smaller repeated impacts rather than prevent concussions. What gives me pause is how an NFL endorsement, amid mixed data, can so quickly turn uncertainty into perceived protection, especially as this gear spreads to youth football.

This is all I have for you today. Thank you for joining and enjoy the big game tomorrow. As always, please reach out with any questions or comments. You can reach me at [email protected]

Yours truly,
Mark Gad